Lonza to buy five US sites from Merck KGaA

By Reuters News

- Contract drug manufacturer Lonza LONN.S will more than double its US footprint after agreeing to buy five manufacturing sites in the country from Merck KGaA MRCG.DE, the Swiss company said on Tuesday.

The deal will bring the number of Lonza's US sites to nine, and expand its cell and gene therapy capabilities, while Germany's Merck continues its shift towards a concentrated life science portfolio.

  • The deal is valued in a range of low- to mid-triple-digit million Swiss francs, the companies said, and is expected to close in the middle of next year.

  • Around 1,100 employees are set to join Lonza's workforce under the transaction.

  • Barclays analysts described the deal as "strategically positive" for Lonza, pointing to upside from utilisation and margin improvement.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.